Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tonix Pharmaceuticals Holding Corp.

NASDAQ: TNXP · Life Sciences · 7 alerts · CIK 1430306

Share price
$2.88Close, Nov 16
Market cap
$56M
Shares outstanding
19.43MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tonix Pharmaceuticals Holding Corp. filings on SEC EDGAR ↗

4:01 PM ET 8-K
Court & Legal Update

Tonix Pharmaceuticals Holding Court & Legal Update

Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.

Counterparty
Dr. Reddy’s Laboratories Ltd.
Term
30 months
8:01 AM ET Form 4
Insider Buying

Tonix Pharmaceuticals Holding CEO Seth Lederman Buys $20.3K of Stock

Seth Lederman, CEO, bought 5,000 shares of Tonix Pharmaceuticals Holding Corp. at $4.05 a share, worth $20.3K in total on Nov 11, 2026. Shares held after the trade: 16,005 (+45.4%).

Value
$20.3K
Shares
5,000
Price
$4.05
Role
CEO
Holding change
+45.4%
Trade date
Nov 11, 2026
8:26 AM ET 10-Q
Financial Results

Tonix Pharmaceuticals Holding Q3 2026 Results: Net Loss of $53.3M, Loss Widens

Tonix Pharmaceuticals reported a significant increase in product revenue to $37.7 million for the first nine months of 2026, up from $7.7 million in 2025, though net losses widened to $134.1 million due to higher R&D and SG&A expenses. The company maintained a cash position of $162.8 million as of September 30, 2026, supported by approximately $81.7 million in net proceeds from common stock issuances during the year.

Key figure
Net loss $53.3M
7:21 AM ET 8-K
Financial Results

Tonix Pharmaceuticals Holding Financial Results

Tonix Pharmaceuticals reported Q3 2026 financial results, highlighted by $15 million in net sales for TONMYA, representing a 37% increase over the prior quarter. The company expanded its sales force to 150 representatives and secured major managed Medicare agreements covering an additional 30 million lives. As of September 30, 2026, the company held approximately $163 million in cash and cash equivalents.

Term
Q3 2026

“We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter. Total prescriptions, new prescriptions, and refills also increased. Payer access expanded to include two commercial group purchasing organization (GPO) agreements, two managed Medicare agreements, and Medicaid access in almost every state.”

Seth Lederman, M.D., President and Chief Executive Officer

“In addition to TONMYA’s growth, we are focused on our core clinical priorities. Our priorities include advancing TNX-102 SL in major depressive disorder (MDD), TNX-4800 for Lyme disease prevention, and the investigator-initiated study of TNX-1500 (mosdaprubart) to prevent kidney transplant rejection.”

Seth Lederman, M.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.